|
Research Management and Support
|
RMS2011 [E]
|
$335,240,650
|
N/A
|
National Cancer Institute
|
|
Cancer Center Support Grant
|
5P30CA013696-38
|
$3,816,425
|
Abate-Shen, Cory
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Phospholipid and Sphingolipid Signaling in Drosophila
|
ZIA BC 010331
|
$486,715
|
Acharya, Jairaj
|
CCR (NCI)
|
|
Sphingolipid Signaling in Mammals
|
ZIA BC 011187
|
$486,715
|
Acharya, Jairaj
|
CCR (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$891,092
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Protein Folding Mechanism
|
ZIA BC 010276
|
$285,604
|
Bai, Yawen
|
CCR (NCI)
|
|
Investigation of the ABC Half-Transporter ABCG2
|
ZIA BC 010622
|
$261,870
|
Bates, Susan
|
CCR (NCI)
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S5
|
$11,164,583
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S6
|
$75,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Molecule-Guided Investigations into p53 Biology
|
ZIA BC 011261
|
$289,758
|
Bernal, Federico
|
CCR (NCI)
|
|
Molecular Interactions that Drive p63 and p73 Function
|
ZIA BC 011376
|
$144,879
|
Bernal, Federico
|
CCR (NCI)
|
|
Studies of Histone Functions in Chromatin; H2AX and DNA DSBs
|
ZIA BC 006140
|
$889,630
|
Bonner, William
|
CCR (NCI)
|
|
Molecular Profiling of Patients Undergoing Radiotherapy
|
ZIA SC 010372
|
$818,472
|
Camphausen, Kevin
|
CCR (NCI)
|
|
The Synergy Between Radiotherapy and Molecularly Targeted Agents
|
ZIA SC 010373
|
$1,227,708
|
Camphausen, Kevin
|
CCR (NCI)
|
|
Radiation Oncology Branch - Radiation Clinic
|
ZID BC 010990
|
$5,456,815
|
Camphausen, Kevin
|
CCR (NCI)
|
|
Novel Treatment of NF-1 Associated Malignant Peripheral Nerve Sheath Tumors
|
5R01CA122804-04
|
$291,849
|
CARROLL, STEVEN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
p21-Activated Kinases as New Therapeutic Targets in Neurofibromatosis Type 1
|
5R01CA142928-02
|
$395,129
|
CHERNOFF, JONATHAN
|
INSTITUTE FOR CANCER RESEARCH
|
|
Elucidating the Function of the NF1 tumor suppressor and its effector pathways in
|
5R01CA111754-07
|
$284,401
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Elucidating the role of the mTOR pathway in NF1-related tumorigenesis
|
5R01CA129814-05
|
$318,505
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Neurofibromatosis type 1 Gene Regulates Myelopoiesis
|
5R01CA074177-14
|
$314,738
|
CLAPP, DAVID
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Mechanisms of Cross-talk Between EphrinB and Alternate Signaling Pathways
|
ZIA BC 010006
|
$489,703
|
Daar, Ira
|
CCR (NCI)
|
|
Signaling Mechanisms of EphrinB1 in Cell Adhesion, Migration and Invasion
|
ZIA BC 010958
|
$489,703
|
Daar, Ira
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
3P30CA013696-38S1
|
$74,998
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-38S2
|
$139,995
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
CANCER AND INFLAMMATION GENETICS
|
ZIA BC 011300
|
$641,770
|
Dean, Michael
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
3P30CA091842-10S1
|
$49,953
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA091842-10S2
|
$75,000
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
5P30CA091842-10
|
$4,380,520
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Clinical Pharmacogenetics
|
ZIA BC 010627
|
$440,189
|
Figg, William
|
CCR (NCI)
|
|
Exploring the Therapeutic Potential of Stem Cell Biology in Gliomas
|
ZIA BC 010839
|
$469,364
|
Fine, Howard
|
CCR (NCI)
|
|
Elucidation and Exploitation of GSK3 as a Novel Glioma Therapeutic Target
|
ZIA BC 010840
|
$469,364
|
Fine, Howard
|
CCR (NCI)
|
|
Canine Glioma and Embryonic Neural Stem Cell Project
|
ZIA BC 011099
|
$469,364
|
Fine, Howard
|
CCR (NCI)
|
|
SCF as a Novel CNS and Glioma-Derived Angiogenic Factor and SC Chemotaxic Factor
|
ZIA BC 011100
|
$469,364
|
Fine, Howard
|
CCR (NCI)
|
|
Identifying New Glioma-Associated Tumor Suppressors and Oncogenes
|
ZIA BC 011101
|
$469,364
|
Fine, Howard
|
CCR (NCI)
|
|
The Role of miRNAs in Glioma Stem Cell and Glioma Biology
|
ZIA BC 011102
|
$536,416
|
Fine, Howard
|
CCR (NCI)
|
|
The Glioma Molecular Diagnostic Initiative: Characterizing Brain Tumor Data
|
ZIA SC 010100
|
$469,364
|
Fine, Howard
|
CCR (NCI)
|
|
Brain Tumor Animal Therapeutics Core
|
ZIC BC 011086
|
$804,624
|
Fine, Howard
|
CCR (NCI)
|
|
Brain Tumor Clinical and Clinical Research Program
|
ZID BC 011098
|
$2,547,976
|
Fine, Howard
|
CCR (NCI)
|
|
Mechanism of Merlin-mediated contact inhibition and tumor suppression.
|
5R01CA152975-02
|
$550,538
|
GIANCOTTI, FILIPPO
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells
|
ZIA BC 005598
|
$548,663
|
Gottesman, Michael
|
CCR (NCI)
|
|
Sensitization of chordoma cell lines to ionizing radiation
|
ZIA BC 011326
|
$198,518
|
Haglund, Karl
|
CCR (NCI)
|
|
Role of Selenium in Development and Health
|
ZIA BC 005317
|
$286,567
|
Hatfield, Dolph
|
CCR (NCI)
|
|
Molecular Pathogenesis of Radiation Enteropathy
|
5R37CA071382-13
|
$275,798
|
Hauer-Jensen, Martin
|
UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK
|
|
Cutaneous Lesions in Neurofibromatosis Type I and Other Pre-cancerous Syndromes
|
ZIA BC 010734
|
$48,425
|
Hornyak, Thomas
|
CCR (NCI)
|
|
Genetic Correlation with Efficacy and Toxicity of Brain Tumor Therapies
|
ZIA BC 011347
|
$43,803
|
Iwamoto, Fabio
|
CCR (NCI)
|
|
Aging and Primary Central Nervous System Tumors
|
ZIA BC 011348
|
$43,803
|
Iwamoto, Fabio
|
CCR (NCI)
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$195,669
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Biomarkers and Therapeutic Targets in Angiogenesis and Metastasis
|
ZIA BC 011334
|
$195,669
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Mechanisms of transcription fidelity in prokaryotes and eukaryotes
|
ZIA BC 010795
|
$384,126
|
Kashlev, Mikhail
|
CCR (NCI)
|
|
Ras-mediated signals in human epithelial cell transformation and metastasis
|
ZIA BC 010607
|
$188,021
|
Kelly, Kathleen
|
CCR (NCI)
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|